).
Results:
This study included 136 HCCs and 42 non-HCC malignancies. Specificity and positive predictive value of an HCC imaging diagnosis (LR-5 or LR-5V) were 69.0% and 90.5%, respectively, for reader 1 (R1) and 88.3% and 95.5%, respectively, for reader 2 (R2). Tumor in vein was a common finding in patients with non-HCC malignancies (R1, 10 of 42 [23.8%] ; R2, five of 42 [11.9%] ). Exclusion of the LR-5V pathway improved specificity and positive predictive value for HCC to 83.3% and 92.9%, respectively, for R1 (six fewer false-positive findings) and 92.3% and 96.4%, respectively, for R2 (one fewer false-positive finding). Among masses with arterial phase hyperenhancement, the rim pattern was more common among non-HCC malignancies than among HCCs for both readers (R1: 24 [17.1%] , P , .001) (k = 0.76). Exclusion of rim arterial phase hyperenhancement as a means of satisfying LR-5 criteria also improved specificity and positive predictive value for HCC (R1, two fewer false-positive findings). diagnostic performance and interrater reliability (IRR) of LI-RADS version 2014 to discriminate among malignant liver lesions in a population of patients at risk for HCC (ie, the population intended for LI-RADS). Specifically, we hypothesized that particular dynamic enhancement patterns, such as rim arterial phase hyperenhancement and washout, would prove most useful.
Materials and Methods

Study Design
This observational Health Insurance Portability and Accountability Actcompliant single-center study was performed retrospectively. Our local institutional review board approved the protocol and waived the informed consent requirement.
Reference Standard
Pathologic analysis is currently the reference standard for differentiating among various malignant liver lesions. Accordingly, it served as the reference Considerable overlap can exist in the imaging appearances of HCC and other primary hepatic malignancies, such as intrahepatic cholangiocarcinoma (ICC) and hepatocholangiocarcinoma (HChC); the latter is also known as primary liver carcinoma with biphenotypic differentiation (5, 6) . Whereas patients with early-stage HCC are eligible for prioritization on organ transplant waiting lists (3), ICC is considered a contraindication for orthotopic liver transplantation at many centers because of poor outcomes (7) . Similarly, HChC likely confers a worse prognosis than does pure HCC (8) , and there is disagreement about whether orthotopic liver transplantation is appropriate in patients with HChC. Because differentiation of HCC from other liver malignancies is of paramount importance for optimal organ allocation, guidelines for diagnosing HCC with imaging have focused on maximizing specificity at the expense of sensitivity (9) . Unfortunately, most sets of guidelines are not sufficiently detailed to achieve uniform implementation by different radiologists, who may have varying interpretations of diagnostic criteria.
To address this issue, the American College of Radiology introduced the Liver Imaging Reporting and Data System (LI-RADS), which provides tools for standardizing the imaging diagnosis of HCC, including a diagnostic algorithm, illustrative atlas, and lexicon (10) . However, little is known about the ability of LI-RADS to help differentiate HCC from other hepatic malignancies. Thus, the aim of our study was to evaluate the 
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Advances in Knowledge
n Rim arterial phase hyperenhancement is significantly more common among patients with non-HCC malignancies than among those with HCCs.
n The differentiation of hepatocholangiocarcinoma (HChC) from HCC is particularly challenging; when counted as a non-HCC malignancy, HChC adversely affects the diagnostic performance of LI-RADS version 2014.
Implications for Patient Care
n Tumor in vein should not be considered diagnostic of HCC unless there is an associated parenchymal mass that independently meets criteria for LR-5.
n Rim arterial phase hyperenhancement should not be used to satisfy LR-5 criteria; hepatic masses with rim arterial phase hyperenhancement should instead be categorized as LR-M.
H epatocellular carcinoma (HCC), the most common primary liver malignancy, is a major cause of morbidity and mortality among patients with chronic liver disease (1) . When recognized at early stages, HCC can be treated with appropriate therapy, which may involve resection, percutaneous ablation, or orthotopic liver transplantation (2). In the United States, current Organ Procurement and Transplantation Network policies stipulate that HCC can be diagnosed with imaging or pathologic analysis (3) . When possible, the former is often preferred to avoid sampling error and potential biopsy complications (4).
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Fraum et al the pathologic diagnoses and classified all masses as malignant or benign. Most, but not all, masses could be readily classified (Fig 1) . 
Imaging Techniques
Study Cohort
Two authors (T.J.F., R.T.) not involved in pathology interpretation or LI-RADS assessment were responsible for identifying candidate liver masses. Our inclusion and exclusion criteria (Fig 1) and liver mass selection algorithm (Fig 2) were designed to collect pathology-proven liver masses with adequate imaging for LI-RADS assessment in patients at risk for HCC. A prospectively compiled pathology database was queried to identify all liver specimens entered between August 2012 and August 2015. The associated clinical histories were reviewed to determine the indication for specimen submission. Because of the high prevalence of metastases and because of our interest in primary liver malignancies, we excluded specimens obtained in patients known or strongly suspected to have active extrahepatic malignancy. Specimens deemed inadequate or nondiagnostic by the pathologist were also excluded (Fig 1) . In the remaining patients, medical records were reviewed to identify individuals with at least one HCC risk factor, per American Association for the † Known or strongly suspected liver mass at time of biopsy; specimens with nonmass indications for liver biopsy (eg, fibrosis, acute liver failure, transaminitis, etc) were excluded.
‡ HCCs diagnosed with imaging and treated with local-regional therapy prior to liver transplantation were excluded if the lesion demonstrated complete necrosis (ie, no residual viable tumor) at explant pathology.
§ Two lesions in which hepatocellular neoplasm of uncertain malignant potential was the final pathologic diagnosis were reviewed in greater detail. In both instances, there was inadequate follow-up (clinical, imaging, or pathology) to confirm the malignant behavior of these masses, so they were considered benign. Notably, premalignant lesions, such as dysplastic nodules, were also considered benign.
|| Patients with remote histories of malignancy were eligible for inclusion on a case-by-case basis depending on the degree of clinical suspicion for recurrent disease. Notably, liver metastases were eligible for inclusion if the patient was not thought to have a primary malignancy outside of the liver at the time of pathology. AASLD = American Association for the Study of Liver Diseases, DCE = dynamic contrast enhanced, LRT = local-regional therapy.
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Fraum et al feature). Readers evaluated the imaging study immediately prior to tissue acquisition unless the lesion had already been treated at that time. In such instances, readers instead evaluated the study immediately prior to treatment. For threshold growth evaluation, readers also had access to prior imaging studies to permit assessment of changes in size.
Statistical Analyses
We searched a pathology database for all liver masses entered over a 3-year period (August 2012 through August 2015). The initial sample size of our study was determined by the number of liver masses meeting inclusion criteria during this period (306 lesions in 220 patients). To avoid clustering effects related to overrepresentation of particular pathologic diagnoses that might be more highly associated with multiplicity, we randomly selected a single mass from each patient to include in the subsequent analysis. This step resulted in a final study cohort of 220 masses (178 malignant, 42 benign) from 220 unique patients. Our sample size of 178 malignant masses (136 HCCs, 42 non-HCC identifying information was provided for examinations containing multiple lesions in proximity to one another. For patients with more than one lesion, we elected to have the readers evaluate all lesions that satisfied the inclusion criteria so as to reflect the commonly encountered scenario of multiple discrete lesions within the liver of an at-risk patient. Each lesion was evaluated independently; however, readers were allowed to consider lesion multiplicity (a LI-RADS ancillary independently evaluated all 306 pathology-proven masses according to LI-RADS version 2014 (10), scoring all major and ancillary features and assigning an overall LI-RADS category ( Fig E2 [online] ). The pathology-proven benign masses ( Fig E3 [online] ) were not considered in our diagnostic performance analysis, with the exception of data pertaining to the IRR of final LI-RADS categories. All lesion locations were specified by series or section number. Additional spatial ‡ The benign lesions were not considered in our diagnostic performance analysis, with the exception of the results reported in Figure 5 and Table 1 . DCE = dynamic contrast-enhanced, LRT = local-regional therapy. 
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Fraum et al dependency and setting the false discovery rate to 5% (15) . Consequently, for all statistical tests, P , .006 was indicative of a significant difference. All statistical analyses were performed with SAS software (version 9.4; SAS Institute, Cary, NC).
Results
Study Cohort
The final study cohort consisted of 178 malignant masses in 178 patients and 42 benign masses in 42 patients (Fig 2) .
of tissue for pathology, prevalence of local-regional therapy between imaging and pathology, and imaging modalities used for LI-RADS assessment. Cohen k and the intraclass correlation coefficient were used to assess IRR for categorical and continuous variables, respectively. Agreement was scored as follows (14) Correction for multiple comparisons was conducted by using the false discovery rate method for malignancies) produces a two-sided 95% confidence interval (CI) with a width of 0.344 or less when the difference in proportions between HCCs and non-HCC malignancies is 10% for a given LI-RADS feature. Differences in mean age by sex and in mean interval between imaging and pathology by category of malignancy were evaluated with the independent samples t test. The Pearson x 2 or Fisher exact test was used to detect significant differences between HCC and non-HCC malignancies with respect to frequency of imaging features, source ‡ Refers to the primary imaging examination selected for LI-RADS assessment.
§ This P value is based on results of the independent samples t test. LRT = localregional therapy, SD = standard deviation.
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Fraum et al Network exception points) versus LR-5. Table 1 shows IRR results for different LI-RADS categories for all 220 pathology-proven masses, including the 42 benign masses that are not considered for the remainder of our diagnostic performance analysis. When we considered all categories, agreement was moderate (k = 0.55; 95% CI: 
Diagnostic Performance of LI-RADS in the Prediction of HCC versus Non-HCC Malignancy
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Fraum et al of satisfying the arterial phase hyperenhancement requirement for LR-5 status improved specificity and positive predictive value for HCC (when it was not already 100%). Table E1 [online]). Reader-assigned LI-RADS categories do not simply reflect particular combinations of major features; rather, they are also influenced by ancillary features and tie-breaking rules. In Table  E2 (online), we isolate the effect of major features by showing how many lesions meet LR-5 or LR-5V criteria simply on the basis of each reader's scoring of the major features. The criteria for the pathways with highest specificity for HCC were infrequently satisfied. The tumor in vein pathway had the lowest positive predictive value for HCC (R1, 58.3%; R2, 58.3%). For all LR-5 pathways, excluding rim arterial phase hyperenhancement as a means but a lower negative predictive value (R1, 43.3%; R2, 42.7%). When both readers agreed on the imaging diagnosis of HCC (ie, LR-5 or LR-5V), specificity and positive predictive value for HCC improved only slightly (data not shown). Interestingly, for R1, the LR-M category had a higher specificity for non-HCC malignancy (92.6%) than the LR-5 category had for HCC (83.3%). However, the LR-M category had a relatively low sensitivity for non-HCC malignancy (R1, 64.3%). Notably, these results are predicated on counting HChCs as non-HCC malignancies. When HChCs were instead counted as HCCs, there was improved sensitivity of LR-M for non-HCC malignancy and improved specificity and positive predictive value of LR-5 or Table 2 Diagnostic Performance of LI-RADS Categories by Reader for Differentiating HCC from Non-HCC Malignancy Note.-For the raw data from which these numbers were derived, please see Table E1 (online). Data in parentheses are 95% CIs.
Frequency and Interrater Reliability of LI-RADS Major Features
* Data derived from counting HChCs as non-HCC malignancies. Outside of this table and Table E1 (online), all other data are based on this premise. † Alternate data derived from counting HChCs as HCCs. These data are presented for purposes of comparison, showing the effects of how HChCs are counted on the diagnostic performance of the LI-RADS categories.
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to pathologic diagnosis and reader-assigned LI-RADS category.
Discussion
Our study provides useful data on the diagnostic performance of LI-RADS in the differentiation of HCC from non-HCC malignancy in a population at risk for HCC and attempts to tackle the difficulties presented by HChCs. Although previous studies have identified imaging features capable of distinguishing HCC from other primary liver malignancies, they have not consistently focused on patients at risk for HCC (16) (17) (18) (19) , used consecutive pathology-proven lesions (including explanted livers) to provide a more realistic reflection of HCC versus non-HCC malignancy prevalence Note.-For the raw data from which these numbers were derived, please see Table E3 (online). Data are numbers of lesions, and data in parentheses are percentages, unless otherwise indicated.
* P values are based on the results of the Pearson x 2 or Fisher exact test. P , .006 indicates a significant difference. † Data in parentheses are 95% CIs.
for two HChCs, two ICCs, and one other non-HCC malignancy but scored only one HChC (and no ICCs or other non-HCC malignancies) as LR-5V. The first lesion showed rim hyperenhancement (arrowhead) in the late arterial phase, with rim washout (arrowhead) and progressive central enhancement (arrow) in the delayed phase. This lesion, which was categorized as LR-M by both readers, was an HChC at pathologic examination. Bottom: The second lesion showed confluent hyperenhancement ( * ) in the late arterial phase, with confluent washout ( * ) in the delayed phase. This lesion, which was categorized as LR-5 by both readers, was an HCC at pathologic examination.
Frequency and Interrater Reliability of LI-RADS Ancillary Features
Figure 7:
Value of rim arterial phase hyperenhancement in predicting non-HCC malignancy. A patient with known cirrhosis underwent liver MR imaging. Top left: T1-weighted late arterial phase MR image shows a segment 6 lesion with rim arterial phase hyperenhancement (arrowheads), as was noted by both readers. Top right: T1-weighted portal venous phase MR image shows that this appearance persists (arrowheads). The readers disagreed with respect to washout and capsule appearance, with one reader noting washout only and the other noting capsule appearance only. Bottom: There was T2 hyperintensity ( * ) (left) and diffusion restriction ( * ) (right), but neither reader noted any features from the "favoring non-HCC malignancy" group. Both readers classified this lesion as LR-5. Pathologic examination revealed an HChC. This case shows the value of rim arterial phase hyperenhancement in predicting non-HCC malignancy and the danger of using rim arterial phase hyperenhancement to satisfy criteria for LR-5.
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found substantial agreement for intralesional fat and moderate agreement for mild-to-moderate T2 hyperintensity, restricted diffusion, distinctive rim, progressive concentric enhancement, liver surface retraction, multiplicity, and central necrosis or ischemia. Three of these eight ancillary features were also significant predictors of HCC versus non-HCC malignancy status for both readers, indicating that these features can be used to distinguish between different types of hepatic malignancy in a reproducible fashion. The remaining ancillary features showed poor to fair agreement, highlighting an opportunity for continued refinement of the LI-RADS lexicon and atlas.
A primary aim of our study was to evaluate the diagnostic performance of LI-RADS in distinguishing HCC from non-HCC malignancy. We found that an imaging diagnosis of HCC (LR-5 or LR-5V) had good specificity (R1: 69.0%; R2: 90.5%) and good positive predictive value (R1: 88.3%; R2: 95.5%) for HCC at pathology; however, specificity was somewhat lower than desired. Others have reported higher specificities (range, 95%-98%) and positive predictive values (range, 96%-100%), but with more stringent inclusion criteria and without consideration of HChCs (20) (21) (22) .
HChCs proved diagnostically challenging, as we had expected based on other studies (5, 29) . Pathologic definitions of HChC have evolved, but they have been inconsistently adopted; therefore, there is considerable variability among institutions in the rate of HChC diagnosis (30) . Furthermore, there is no consensus regarding HChC management. To address this issue and to estimate a magnitude of effect, we analyzed the diagnostic performance of LI-RADS when counting HChCs as HCCs instead of as non-HCC malignancies. When HChCs were counted as HCCs, specificity and positive predictive value of LR-5 for HCC and sensitivity of LR-M for non-HCC malignancy substantially improved, indicating considerable overlap in the imaging appearances of HChC and HCC. When HChCs were instead counted as non-HCC malignancies, the HChCs misclassified as (26) (27) (28) .
Our study also assessed IRR for individual LI-RADS ancillary features. We (16, 17) , or explicitly addressed HChC as a discrete pathologic diagnosis (18, (20) (21) (22) (23) (24) (25) .
When we considered all LI-RADS categories (for all benign and malignant lesions), agreement was moderate (k = 0.55; 95% CI: 0.47, 0.63) and compared favorably with that reported in previous publications (k = 0.43-0.45) (26) (27) (28) . For the purposes of transplant listing, liver mass categorization is essentially binary (ie, LR-5 vs not LR-5), as the LR-5 category alone grants eligibility for Organ Procurement and Transplantation Network exception points (provided the Milan criteria are also satisfied). Agreement improved to A patient with known cirrhosis (note liver surface nodularity) underwent liver MR imaging. T1-weighted images acquired in the late arterial phase show a segment 8 lesion ( * ) that both readers scored as having confluent arterial phase hyperenhancement. One reader also noted subtle areas of nodular washout (arrowheads) on the portal venous phase images. Along the inferior margin of the lesion on the first set of delayed images was a T1 hypointense branching structure (arrow) that imbibed contrast material on the second set of delayed images. This finding is consistent with tumor in vein, as noted by both readers. One reader classified this lesion as LR-5V, whereas the other reader (the one who did not score washout as present) classified it as LR-M instead of LR-5V after applying tie-breaking rules. Subsequent biopsy revealed an ICC. This case shows that ICCs can adopt atypical hypervascular appearances in the setting of cirrhosis and highlights our finding that tumor in vein is commonly observed among hepatic malignancies other than HCC.
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Fraum et al LR-5V (R1, three masses). None of these ICCs demonstrated rim arterial phase hyperenhancement or ancillary features from the "favoring non-HCC malignancy" group, with the exception of one ICC with liver surface retraction classified as LR-5V by R1. Other studies have identified small ICCs as potential HCC mimics (6); however, the misclassified ICCs in our study were quite large (range, 4.7-13.2 cm). Interestingly, confluent arterial phase hyperenhancement, non-rim washout, or both were described for three ICCs misclassified as LR-5 or LR-5V, corroborating the notion that ICCs can demonstrate a hypervascular appearance in the setting of chronic liver disease (34) . A surprising finding was the frequency of tumor in vein among patients with non-HCC malignancies. Tumor in vein was common among those LR-5 or LR-5V did not exhibit any ancillary features from the "favoring non-HCC malignancy" group; however, several lesions (R1, two masses) misclassified as LR-5 did demonstrate rim arterial phase hyperenhancement, a feature more common among non-HCC malignancies in our study. Thus, the exclusion of rim arterial phase hyperenhancement as an acceptable major feature for the imaging diagnosis of HCC would likely improve the specificity and positive predictive value of the LI-RADS algorithm.
LI-RADS proved quite reliable in distinguishing HCCs from ICCs when compared with distinguishing HCCs from HChCs, as has been previously reported (31 Note.-For the raw data from which these numbers were derived, see Table E6 (online). Data are number of lesions, and data in parentheses are percentages, unless otherwise indicated.
* P values are based on the results of the Pearson x 2 or Fisher exact test. P , .006 indicates a significant difference. † Data in parentheses are the 95% CI. Our study had several limitations, including its retrospective single-center design. Masses with atypical imaging features (ie, those requiring biopsy for definitive diagnosis) may be overrepresented due to the pathology reference standard. However, liver explantation or resection (ie, therapies suggesting the presence of imaging features sufficiently characteristic to prompt definitive management) was the tissue source for the majority of masses, thereby mitigating some of this bias. Non-HCC malignancies were uncommon (relative to HCCs) and required aggregation for analysis, precluding head-to-head comparisons of individual pathologic entities. Although the high ratio of HCCs to non-HCC malignancies in our study likely reflects their relative frequencies in an at-risk population, our inclusion of some masses from which tissue was obtained via percutaneous biopsy may have resulted in underrepresentation of HChCs (eg, if only the hepatocellular portions of the mass were sampled). Finally, because our study was restricted to pathology-proven malignant lesions, the values we report for sensitivity, specificity, and positive and negative predictive values are likely somewhat different from those that would be obtained in a prospective study including malignant and benign masses at their natural frequencies.
In conclusion, modification of the algorithmic role of tumor in vein and rim arterial phase hyperenhancement improves the diagnostic performance of LI-RADS version 2014 in the differentiation of HCC from non-HCC malignancy. IRR was moderate to substantial for both overall LI-RADS category and most major features. ICCs were misclassified in a minority of instances, whereas HChCs proved more challenging to differentiate from HCC, negatively affecting diagnostic performance. Rim arterial phase hyperenhancement may be a useful feature with which to differentiate HChCs from HCCs. Tumor in vein was commonly observed among non-HCC malignancies and consequently should not be used in isolation to diagnose HCC with imaging.
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